|
End-of-day quote
Korea S.E.
08/05/2026
|
5-day change
|
1st Jan Change
|
|
198,400.00 KRW
|
-2.02%
|
 |
-1.05%
|
+9.61%
|
|
05-08 |
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on April 22, 2026.
|
CI
| |
05-06 |
Celltrion's Net Attributable Income Jumps 219% in Q1
|
MT
| |
05-06 |
Celltrion to Retire KRW100 Billion Worth of Treasury Shares
|
MT
| |
05-06 |
Celltrion Q1 operating profit 322 billion won, up 115% Y/Y
|
RE
| |
05-06 |
Celltrion to cancel 100 billion won treasury shares
|
RE
| |
05-05 |
Celltrion, Inc.'s Equity Buyback announced on April 22, 2026, has expired with 488,977 shares, representing 0.22% for KRW 99,999.87 million.
|
CI
| |
04-29 |
Celltrion, Inc. agreed to acquire Gifrer Barbezat SAS.
|
CI
| |
04-22 |
Celltrion, Inc. authorizes a Buyback Plan.
|
CI
| |
04-22 |
Celltrion, Inc. announces an Equity Buyback for 492,611 shares.
|
CI
| |
04-22 |
Celltrion to buy 100 billion won of own shares
|
RE
| |
03-23 |
Worker Dies After Fatal Fall at Celltrion's Incheon Plant; Shares Decline 6%
|
MT
| |
03-17 |
Celltrion Secures Pharmaceutical Manufacturing Contract; Shares Rise 3%
|
MT
| |
03-16 |
Celltrion Inc Announces U S Availability Of AVTOZMA® (tocilizumab-anoh) Subcutaneous (SC) Formulation
|
CI
| |
03-16 |
Celltrion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
|
CI
| |
03-09 |
Celltrion Expands Treasury Share Cancellation
|
MT
| |
01-14 |
Celltrion Presents Innovative Drug Pipeline and U.S. Manufacturing and R&D Expansion Strategy At the 44Th Annual J.P. Morgan Healthcare Conference
|
CI
| |
01-02 |
Celltrion Shares Rally on U.S. Contract, Earnings Outlook
|
DJ
| |
12-18 |
Celltrion, Inc. Receives Positive CHMP Opinion for SteQeyma (Uustekinumab Biosimilar) Autoinjector
|
CI
| |
12-10 |
Celltrion, Inc. announces Annual dividend
|
CI
| |
12-03 |
Celltrion Announces U.S. FDA Approval of 300mg strength of OMLYCLO®?
|
CI
| |
11-28 |
Celltrion, Inc. Receives Health Canada Approval for Eydenzelt®?, a Biosimilar Confirming Eylea®? (aflibercept 2Mg)
|
CI
| |
11-26 |
Celltrion Announces Publication of Post-Hoc Analysis of Liberty-Cd Study of Zymfentra®? (Infliximab-Dyyb)
|
CI
| |
11-18 |
Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo?? 300Mg
|
CI
| |
11-18 |
Celltrion, Inc Announces European Commission Grants Approval of Remsima?? IV Liquid Formulation, World's First Liquid Formulation of IV Infliximab
|
CI
| |
11-14 |
Celltrion, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
|
CI
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
